INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 342 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $528,653 | -81.7% | 15,152 | -70.6% | 0.00% | -66.7% |
| Q3 2022 | $2,886,000 | -86.9% | 51,571 | -87.9% | 0.00% | -88.5% |
| Q2 2022 | $22,068,000 | +39.0% | 426,350 | +95.2% | 0.03% | +73.3% |
| Q1 2022 | $15,872,000 | +5003.5% | 218,409 | +8191.9% | 0.02% | – |
| Q4 2021 | $311,000 | -90.7% | 2,634 | -89.5% | 0.00% | -100.0% |
| Q3 2021 | $3,358,000 | -84.0% | 25,032 | -80.7% | 0.00% | -83.3% |
| Q2 2021 | $21,047,000 | -35.0% | 129,992 | -67.8% | 0.02% | -41.9% |
| Q1 2021 | $32,400,000 | +64.8% | 403,720 | +11.7% | 0.03% | +72.2% |
| Q4 2020 | $19,659,000 | +475.0% | 361,371 | +110.1% | 0.02% | +500.0% |
| Q3 2020 | $3,419,000 | -16.4% | 171,969 | -11.6% | 0.00% | -40.0% |
| Q2 2020 | $4,088,000 | +2109.7% | 194,461 | +1440.3% | 0.01% | – |
| Q4 2019 | $185,000 | – | 12,625 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |